Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash & Current Investments: 2019-2025

Historic Cash & Current Investments for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $1.9 billion.

  • Revolution Medicines' Cash & Current Investments rose 24.66% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 billion, marking a year-over-year increase of 26.34%. This contributed to the annual value of $2.3 billion for FY2024, which is 23.55% up from last year.
  • As of Q3 2025, Revolution Medicines' Cash & Current Investments stood at $1.9 billion, which was down 9.62% from $2.1 billion recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Cash & Current Investments registered a high of $2.3 billion during Q4 2024, and its lowest value of $461.4 million during Q2 2022.
  • Over the past 3 years, Revolution Medicines' median Cash & Current Investments value was $1.7 billion (recorded in 2024), while the average stood at $1.6 billion.
  • As far as peak fluctuations go, Revolution Medicines' Cash & Current Investments declined by 28.61% in 2022, and later surged by 187.31% in 2023.
  • Revolution Medicines' Cash & Current Investments (Quarterly) stood at $577.1 million in 2021, then increased by 11.76% to $644.9 million in 2022, then soared by 187.31% to $1.9 billion in 2023, then rose by 23.55% to $2.3 billion in 2024, then rose by 24.66% to $1.9 billion in 2025.
  • Its Cash & Current Investments stands at $1.9 billion for Q3 2025, versus $2.1 billion for Q2 2025 and $2.1 billion for Q1 2025.